MedTrace Logo

Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria

NCT00724698 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3011

Last updated 2022-02-09

Study results available
· View outcomes & findings →

Summary

Eligible patients will be prescribed Desloratadine 1 tablet of 5 mg once daily. Patients will be asked to follow-up for a final visit after 14 days (Day 15) where the safety, tolerability and clinical efficacy will be measured.

Conditions

  • Rhinitis
  • Urticaria

Interventions

DRUG

Desloratadine

Desloratadine 5 mg once daily

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2007-12-31
Completion
2007-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00724698 on ClinicalTrials.gov